Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9646367 | Schizophrenia Research | 2005 | 8 Pages |
Abstract
These data suggest that polymorphisms in the GRM3 gene may be useful as predictors of negative symptom improvement in persons with schizophrenia treated with olanzapine.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Jeffrey R. Bishop, Vicki L. Ellingrod, Jessica Moline, Del Miller,